{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T07:47:59Z","timestamp":1794815279886,"version":"4.9.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70113873"],"award-info":[{"award-number":["70113873"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["KU2682\/6-1"],"award-info":[{"award-number":["KU2682\/6-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["16LW0220"],"award-info":[{"award-number":["16LW0220"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Claudia v. Schilling Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Mol Med"],"published-print":{"date-parts":[[2025,2,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Oncolytic viruses (OV) expressing bispecific T-cell engagers (BiTEs) are promising tools for tumor immunotherapy but the range of target tumors is limited. To facilitate effective T-cell stimulation with broad-range applicability, we established membrane-associated T-cell engagers (MATEs) harboring the protein transduction domain of the HIV-Tat protein to achieve non-selective binding to target cells. In vitro, MATEs effectively activated murine T cells and improved killing of MC38 colon carcinoma cells. Similarly, humanized MATEs activated T cells in PBMCs from human donors. In MC38-tumors in mice, MATE-expression by the oncolytic adenovirus Ad5\/11 facilitated intratumoral T-cell activation, reduced tumor growth and prolonged survival accompanied by infiltration of tumor-directed CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells and improved CD8\/CD4 T-cell ratio. Absence of early T-cell activation in tumor draining lymph nodes suggests the safe applicability of this strategy. Furthermore, MATE-expression by Ad5\/11 was capable of breaking resistance to \u03b1PD-1 checkpoint therapy thereby promoting T-cell\/tumor cell proximity and clustering of CD8\n                    <jats:sup>+<\/jats:sup>\n                    and CD4\n                    <jats:sup>+<\/jats:sup>\n                    T cells. In summary, we demonstrated that MATE expressing OVs are powerful T-cell activating tools suitable for local immunotherapy of a broad range of tumors.\n                  <\/jats:p>","DOI":"10.1038\/s44321-024-00187-y","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T10:29:13Z","timestamp":1736418553000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Oncolytic viruses expressing MATEs facilitate target-independent T-cell activation in tumors"],"prefix":"10.1038","volume":"17","author":[{"given":"Malin","family":"Peter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Mundt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Menze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Woller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valery","family":"Volk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda M","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon A","family":"\u00d6hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiner","family":"Wedemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Falk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich","family":"Feuerhake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas C","family":"Wirth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6942-1573","authenticated-orcid":false,"given":"Florian","family":"K\u00fchnel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"key":"187_CR1","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1084\/jem.20100348","volume":"207","author":"A Bachem","year":"2010","unstructured":"Bachem A, G\u00fcttler S, Hartung E, Ebstein F, Schaefer M, Tannert A, Salama A, Movassaghi K, Opitz C, Mages HW et al (2010) Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells. J Exp Med 207:1273\u20131281","journal-title":"J Exp Med"},{"key":"187_CR2","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/0008-5472.CAN-09-0547","volume":"69","author":"PA Baeuerle","year":"2009","unstructured":"Baeuerle PA, Reinhardt C (2009) Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 69:4941\u20134944","journal-title":"Cancer Res"},{"key":"187_CR3","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","volume":"321","author":"R Bargou","year":"2008","unstructured":"Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M et al (2008) Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321:974\u2013977","journal-title":"Science"},{"key":"187_CR4","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.ccr.2012.04.025","volume":"21","author":"LJ Bayne","year":"2012","unstructured":"Bayne LJ, Beatty GL, Jhala N, Clark CE, Rhim AD, Stanger BZ, Vonderheide RH (2012) Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 21:822\u2013835","journal-title":"Cancer Cell"},{"key":"187_CR5","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.4161\/cbt.7.8.6216","volume":"7","author":"F Benencia","year":"2008","unstructured":"Benencia F, Courr\u00e8ges MC, Fraser NW, Coukos G (2008) Herpes virus oncolytic therapy reverses tumor immune dysfunction and facilitates tumor antigen presentation. Cancer Biol Ther 7:1194\u20131205","journal-title":"Cancer Biol Ther"},{"key":"187_CR6","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1158\/0008-5472.CAN-04-3527","volume":"65","author":"KM Bernt","year":"2005","unstructured":"Bernt KM, Ni S, Tieu A-T, Lieber A (2005) Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy. Cancer Res 65:4343\u20134352","journal-title":"Cancer Res"},{"key":"187_CR7","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1089\/hum.2007.017","volume":"18","author":"S Bortolanza","year":"2007","unstructured":"Bortolanza S, Alzuguren P, Bu\u00f1uales M, Qian C, Prieto J, Hernandez-Alcoceba R (2007) Human adenovirus replicates in immunocompetent models of pancreatic cancer in Syrian hamsters. Hum Gene Ther 18:681\u2013690","journal-title":"Hum Gene Ther"},{"key":"187_CR8","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/mt.2009.9","volume":"17","author":"S Bortolanza","year":"2009","unstructured":"Bortolanza S, Bunuales M, Otano I, Gonzalez-Aseguinolaza G, Ortiz-de-Solorzano C, Perez D, Prieto J, Hernandez-Alcoceba R (2009) Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in Syrian hamsters. Mol Ther 17:614\u2013622","journal-title":"Mol Ther"},{"key":"187_CR9","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/sj.mt.6300215","volume":"15","author":"CJ Breitbach","year":"2007","unstructured":"Breitbach CJ, Paterson JM, Lemay CG, Falls TJ, McGuire A, Parato KA, Stojdl DF, Daneshmand M, Speth K, Kirn D et al (2007) Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther 15:1686\u20131693","journal-title":"Mol Ther"},{"key":"187_CR10","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I (2017) Elements of cancer immunity and the cancer-immune set point. Nature 541:321\u2013330","journal-title":"Nature"},{"key":"187_CR11","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/ijc.10557","volume":"100","author":"T Dreier","year":"2002","unstructured":"Dreier T, Lorenczewski G, Brandl C, Hoffmann P, Syring U, Hanakam F, Kufer P, Riethmuller G, Bargou R, Baeuerle PA (2002) Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer 100:690\u2013697","journal-title":"Int J Cancer"},{"key":"187_CR12","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1146\/annurev.immunol.22.012703.104803","volume":"22","author":"GP Dunn","year":"2004","unstructured":"Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22:329\u2013360","journal-title":"Annu Rev Immunol"},{"key":"187_CR13","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/mt.2014.160","volume":"22","author":"CE Engeland","year":"2014","unstructured":"Engeland CE, Grossardt C, Veinalde R, Bossow S, Lutz D, Kaufmann JK, Shevchenko I, Umansky V, Nettelbeck DM, Weichert W et al (2014) CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. Mol Ther 22:1949\u20131959","journal-title":"Mol Ther"},{"key":"187_CR14","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.ccell.2024.05.025","volume":"42","author":"G Espinosa-Carrasco","year":"2024","unstructured":"Espinosa-Carrasco G, Chiu E, Scrivo A, Zumbo P, Dave A, Betel D, Kang SW, Jang H-J, Hellmann MD, Burt BM et al (2024) Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors. Cancer Cell 42:1202\u20131216.e8","journal-title":"Cancer Cell"},{"key":"187_CR15","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1158\/0008-5472.CAN-16-1708","volume":"77","author":"CA Fajardo","year":"2017","unstructured":"Fajardo CA, Guedan S, Rojas LA, Moreno R, Arias-Badia M, de Sostoa J, June CH, Alemany R (2017) Oncolytic adenoviral delivery of an EGFR-targeting T-cell engager improves antitumor efficacy. Cancer Res 77:2052\u20132063","journal-title":"Cancer Res"},{"key":"187_CR16","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1073\/pnas.91.2.664","volume":"91","author":"S Fawell","year":"1994","unstructured":"Fawell S, Seery J, Daikh Y, Moore C, Chen LL, Pepinsky B, Barsoum J (1994) Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci USA 91:664\u2013668","journal-title":"Proc Natl Acad Sci USA"},{"key":"187_CR17","doi-asserted-by":"crossref","first-page":"1396490","DOI":"10.3389\/fonc.2024.1396490","volume":"14","author":"CJ Ferreri","year":"2024","unstructured":"Ferreri CJ, Bhutani M (2024) Mechanisms and management of CAR T toxicity. Front Oncol 14:1396490","journal-title":"Front Oncol"},{"key":"187_CR18","doi-asserted-by":"crossref","first-page":"6852","DOI":"10.1158\/0008-5472.CAN-18-1750","volume":"78","author":"JD Freedman","year":"2018","unstructured":"Freedman JD, Duffy MR, Lei-Rossmann J, Muntzer A, Scott EM, Hagel J, Campo L, Bryant RJ, Verrill C, Lambert A et al (2018) An oncolytic virus expressing a T-cell engager simultaneously targets cancer and immunosuppressive stromal cells. Cancer Res 78:6852\u20136865","journal-title":"Cancer Res"},{"key":"187_CR19","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.15252\/emmm.201707567","volume":"9","author":"JD Freedman","year":"2017","unstructured":"Freedman JD, Hagel J, Scott EM, Psallidas I, Gupta A, Spiers L, Miller P, Kanellakis N, Ashfield R, Fisher KD et al (2017) Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies. EMBO Mol Med 9:1067\u20131087","journal-title":"EMBO Mol Med"},{"key":"187_CR20","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","volume":"366","author":"M Gerlinger","year":"2012","unstructured":"Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A et al (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883\u2013892","journal-title":"N Engl J Med"},{"key":"187_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1399-0039.1996.tb02509.x","volume":"47","author":"LK Gilliland","year":"1996","unstructured":"Gilliland LK, Norris NA, Marquardt H, Tsu TT, Hayden MS, Neubauer MG, Yelton DE, Mittler RS, Ledbetter JA (1996) Rapid and reliable cloning of antibody variable regions and generation of recombinant single chain antibody fragments. Tissue Antigens 47:1\u201320","journal-title":"Tissue Antigens"},{"key":"187_CR22","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1093\/nar\/gkp374","volume":"37","author":"E Gurlevik","year":"2009","unstructured":"Gurlevik E, Woller N, Schache P, Malek NP, Wirth TC, Zender L, Manns MP, Kubicka S, Kuhnel F (2009) p53-dependent antiviral RNA-interference facilitates tumor-selective viral replication. Nucleic Acids Res 37:e84\u2013e84","journal-title":"Nucleic Acids Res"},{"key":"187_CR23","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.imbio.2008.11.014","volume":"214","author":"C Haas","year":"2009","unstructured":"Haas C, Krinner E, Brischwein K, Hoffmann P, Lutterb\u00fcse R, Schlereth B, Kufer P, Baeuerle PA (2009) Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. Immunobiology 214:441\u2013453","journal-title":"Immunobiology"},{"key":"187_CR24","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13045-021-01075-5","volume":"14","author":"JPW Heidbuechel","year":"2021","unstructured":"Heidbuechel JPW, Engeland CE (2021) Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies. J Hematol Oncol 14:63","journal-title":"J Hematol Oncol"},{"key":"187_CR25","first-page":"474","volume":"61","author":"A Ho","year":"2001","unstructured":"Ho A, Schwarze SR, Mermelstein SJ, Waksman G, Dowdy SF (2001) Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo. Cancer Res 61:474\u2013477","journal-title":"Cancer Res"},{"key":"187_CR26","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ijc.20908","volume":"115","author":"P Hoffmann","year":"2005","unstructured":"Hoffmann P, Hofmeister R, Brischwein K, Brandl C, Crommer S, Bargou R, Itin C, Prang N, Baeuerle PA (2005) Serial killing of tumor cells by cytotoxic T cells redirected with a CD19\u2010\/CD3\u2010bispecific single\u2010chain antibody construct. Int J Cancer 115:98\u2013104","journal-title":"Int J Cancer"},{"key":"187_CR27","doi-asserted-by":"crossref","first-page":"1126969","DOI":"10.3389\/fimmu.2023.1126969","volume":"14","author":"Y Jia","year":"2023","unstructured":"Jia Y, Wang Y, Dunmall LSC, Lemoine NR, Wang P, Wang Y (2023) Syrian hamster as an ideal animal model for evaluation of cancer immunotherapy. Front Immunol 14:1126969","journal-title":"Front Immunol"},{"key":"187_CR28","first-page":"609","volume":"62","author":"EA Kashentseva","year":"2002","unstructured":"Kashentseva EA, Seki T, Curiel DT, Dmitriev IP (2002) Adenovirus targeting to c-erbB-2 oncoprotein by single-chain antibody fused to trimeric form of adenovirus receptor ectodomain. Cancer Res 62:609\u2013616","journal-title":"Cancer Res"},{"key":"187_CR29","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1158\/2326-6066.CIR-14-0124-T","volume":"3","author":"A Kloos","year":"2015","unstructured":"Kloos A, Woller N, G\u00fcrlevik E, Ureche CI, Niemann J, Armbrecht N, Martin NT, Geffers R, Manns MP, Gerardy-Schahn R et al (2015) Polysia-specific retargeting of oncolytic viruses triggers tumor-specific immune responses and facilitates therapy of disseminated lung cancer. Cancer Immunol Res 3:751\u2013763","journal-title":"Cancer Immunol Res"},{"key":"187_CR30","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/mt.2010.312","volume":"19","author":"J Li","year":"2011","unstructured":"Li J, O\u2019Malley M, Urban J, Sampath P, Guo ZS, Kalinski P, Thorne SH, Bartlett DL (2011) Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer. Mol Ther 19:650\u2013657","journal-title":"Mol Ther"},{"key":"187_CR31","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41586-023-06623-2","volume":"623","author":"AL Ling","year":"2023","unstructured":"Ling AL, Solomon IH, Landivar AM, Nakashima H, Woods JK, Santos A, Masud N, Fell G, Mo X, Yilmaz AS et al (2023) Clinical trial links oncolytic immunoactivation to survival in glioblastoma. Nature 623:157\u2013166","journal-title":"Nature"},{"key":"187_CR32","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood.V95.6.2098","volume":"95","author":"A L\u00f6ffler","year":"2000","unstructured":"L\u00f6ffler A, Kufer P, Lutterb\u00fcse R, Zettl F, Daniel PT, Schwenkenbecher JM, Riethm\u00fcller G, D\u00f6rken B, Bargou RC (2000) A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 95:2098\u20132103","journal-title":"Blood"},{"key":"187_CR33","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1089\/hum.1998.9.17-2577","volume":"9","author":"H Mizuguchi","year":"1998","unstructured":"Mizuguchi H, Kay MA (1998) Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum Gene Ther 9:2577\u20132583","journal-title":"Hum Gene Ther"},{"key":"187_CR34","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1517\/17425247.3.6.739","volume":"3","author":"CL Murriel","year":"2006","unstructured":"Murriel CL, Dowdy SF (2006) Influence of protein transduction domains on intracellular delivery of macromolecules. Expert Opin Drug Deliv 3:739\u2013746","journal-title":"Expert Opin Drug Deliv"},{"key":"187_CR35","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.ymthe.2004.02.019","volume":"9","author":"M Nakamori","year":"2004","unstructured":"Nakamori M, Fu X, Rousseau R, Chen S-Y, Zhang X (2004) Destruction of nonimmunogenic mammary tumor cells by a fusogenic oncolytic herpes simplex virus induces potent antitumor immunity. Mol Ther 9:658\u2013665","journal-title":"Mol Ther"},{"key":"187_CR36","doi-asserted-by":"crossref","first-page":"4374","DOI":"10.1158\/1078-0432.CCR-09-0334","volume":"15","author":"RJ Prestwich","year":"2009","unstructured":"Prestwich RJ, Ilett EJ, Errington F, Diaz RM, Steele LP, Kottke T, Thompson J, Galivo F, Harrington KJ, Pandha HS et al (2009) Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. Clin Cancer Res 15:4374\u20134381","journal-title":"Clin Cancer Res"},{"key":"187_CR37","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1158\/0008-5472.CAN-08-1160","volume":"69","author":"E Ramakrishna","year":"2009","unstructured":"Ramakrishna E, Woller N, Mundt B, Knocke S, G\u00fcrlevik E, Saborowski M, Malek N, Manns MP, Wirth T, K\u00fchnel F et al (2009) Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses. Cancer Res 69:1448\u20131458","journal-title":"Cancer Res"},{"key":"187_CR38","doi-asserted-by":"crossref","first-page":"6643","DOI":"10.1158\/0008-5472.CAN-18-0933","volume":"78","author":"AR S\u00e1nchez-Paulete","year":"2018","unstructured":"S\u00e1nchez-Paulete AR, Teijeira \u00c1, Quetglas JI, Rodr\u00edguez-Ruiz ME, S\u00e1nchez-Arr\u00e1ez \u00c1, Labiano S, Etxeberria I, Azpilikueta A, Bola\u00f1os E, Ballesteros-Briones MC et al (2018) Intratumoral immunotherapy with XCL1 and sFlt3L encoded in recombinant semliki forest virus-derived vectors fosters dendritic cell-mediated T-cell cross-priming. Cancer Res 78:6643\u20136654","journal-title":"Cancer Res"},{"key":"187_CR39","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/j.ymthe.2018.06.001","volume":"26","author":"JM Santos","year":"2018","unstructured":"Santos JM, Cervera-Carrascon V, Havunen R, Zafar S, Siurala M, Sorsa S, Anttila M, Kanerva A, Hemminki A (2018) Adenovirus coding for interleukin-2 and tumor necrosis factor alpha replaces lymphodepleting chemotherapy in adoptive T cell therapy. Mol Ther 26:2243\u20132254","journal-title":"Mol Ther"},{"key":"187_CR40","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1126\/science.285.5433.1569","volume":"285","author":"SR Schwarze","year":"1999","unstructured":"Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF (1999) In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285:1569\u20131572","journal-title":"Science"},{"key":"187_CR41","doi-asserted-by":"crossref","first-page":"1700187","DOI":"10.1002\/mabi.201700187","volume":"18","author":"EM Scott","year":"2018","unstructured":"Scott EM, Duffy MR, Freedman JD, Fisher KD, Seymour LW (2018) Solid tumor immunotherapy with T cell engager\u2010armed oncolytic viruses. Macromol Biosci 18:1700187","journal-title":"Macromol Biosci"},{"key":"187_CR42","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1186\/s40425-019-0807-6","volume":"7","author":"EM Scott","year":"2019","unstructured":"Scott EM, Jacobus EJ, Lyons B, Frost S, Freedman JD, Dyer A, Khalique H, Taverner WK, Carr A, Champion BR et al (2019) Bi- and tri-valent T cell engagers deplete tumour-associated macrophages in cancer patient samples. J Immunother Cancer 7:320","journal-title":"J Immunother Cancer"},{"key":"187_CR43","doi-asserted-by":"crossref","first-page":"5763","DOI":"10.1200\/JCO.2009.24.3675","volume":"27","author":"NN Senzer","year":"2009","unstructured":"Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, Gonzalez R, Glaspy J, Whitman E, Harrington K et al (2009) Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor\u2013encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 27:5763\u20135771","journal-title":"J Clin Oncol"},{"key":"187_CR44","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1535-6108(03)00241-1","volume":"4","author":"DF Stojdl","year":"2003","unstructured":"Stojdl DF, Lichty BD, TenOever BR, Paterson JM, Power AT, Knowles S, Marius R, Reynard J, Poliquin L, Atkins H et al (2003) VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4:263\u2013275","journal-title":"Cancer Cell"},{"key":"187_CR45","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1248\/cpb.c16-00505","volume":"64","author":"T Takeuchi","year":"2016","unstructured":"Takeuchi T, Futaki S (2016) Current understanding of direct translocation of arginine-rich cell-penetrating peptides and its internalization mechanisms. Chem Pharm Bull 64:1431\u20131437","journal-title":"Chem Pharm Bull"},{"key":"187_CR46","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1158\/0008-5472.CAN-05-3497","volume":"66","author":"MA Thomas","year":"2006","unstructured":"Thomas MA, Spencer JF, La Regina MC, Dhar D, Tollefson AE, Toth K, Wold WSM (2006) Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. Cancer Res 66:1270\u20131276","journal-title":"Cancer Res"},{"key":"187_CR47","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443\u20132454","journal-title":"N Engl J Med"},{"key":"187_CR48","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","volume":"29","author":"MS Topp","year":"2011","unstructured":"Topp MS, Kufer P, G\u00f6kbuget N, Goebeler M, Klinger M, Neumann S, Horst HA, Raff T, Viardot A, Schmid M et al (2011) Targeted therapy with the T-cell - engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 29:2493\u20132498","journal-title":"J Clin Oncol"},{"key":"187_CR49","doi-asserted-by":"crossref","first-page":"6679","DOI":"10.1158\/1078-0432.CCR-12-0979","volume":"18","author":"JR Tysome","year":"2012","unstructured":"Tysome JR, Li X, Wang S, Wang P, Gao D, Du P, Chen D, Gangeswaran R, Chard LS, Yuan M et al (2012) A novel therapeutic regimen to eradicate established solid tumors with an effective induction of tumor-specific immunity. Clin Cancer Res 18:6679\u20136689","journal-title":"Clin Cancer Res"},{"key":"187_CR50","doi-asserted-by":"crossref","first-page":"8285","DOI":"10.1158\/0008-5472.CAN-07-1025","volume":"67","author":"A Vigil","year":"2007","unstructured":"Vigil A, Park M-S, Martinez O, Chua MA, Xiao S, Cros JF, Mart\u00ednez-Sobrido L, Woo SLC, Garc\u00eda-Sastre A (2007) Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res 67:8285\u20138292","journal-title":"Cancer Res"},{"key":"187_CR51","volume":"8","author":"P Wang","year":"2017","unstructured":"Wang P, Li X, Wang J, Gao D, Li Y, Li H, Chu Y, Zhang Z, Liu H, Jiang G et al (2017) Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent. Nat Commun 8:1395","journal-title":"Nat Commun"},{"key":"187_CR52","first-page":"3181","volume":"63","author":"T Wirth","year":"2003","unstructured":"Wirth T, Zender L, Schulte B, Mundt B, Plentz R, Rudolph KL, Manns M, Kubicka S, K\u00fchnel F (2003) A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. Cancer Res 63:3181\u20133188","journal-title":"Cancer Res"},{"key":"187_CR53","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/nprot.2006.62","volume":"1","author":"I Wittig","year":"2006","unstructured":"Wittig I, Braun H-P, Sch\u00e4gger H (2006) Blue native PAGE. Nat Protoc 1:418\u2013428","journal-title":"Nat Protoc"},{"key":"187_CR54","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nature14001","volume":"515","author":"M Yadav","year":"2014","unstructured":"Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, Franci C, Cheung TK, Fritsche J, Weinschenk T et al (2014) Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515:572\u2013576","journal-title":"Nature"},{"key":"187_CR55","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1038\/mt.2012.116","volume":"20","author":"A-M Young","year":"2012","unstructured":"Young A-M, Archibald KM, Tookman LA, Pool A, Dudek K, Jones C, Williams SL, Pirlo KJ, Willis AE, Lockley M et al (2012) Failure of translation of human adenovirus mRNA in murine cancer cells can be partially overcome by L4-100K expression in vitro and in vivo. Mol Ther 20:1676\u20131688","journal-title":"Mol Ther"},{"key":"187_CR56","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/mt.2013.240","volume":"22","author":"F Yu","year":"2014","unstructured":"Yu F, Wang X, Guo ZS, Bartlett DL, Gottschalk SM, Song X-T (2014) T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy. Mol Ther 22:102\u2013111","journal-title":"Mol Ther"},{"key":"187_CR57","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S0006-3495(04)74101-6","volume":"86","author":"A Ziegler","year":"2004","unstructured":"Ziegler A, Seelig J (2004) Interaction of the protein transduction domain of HIV-1 TAT with heparan sulfate: binding mechanism and thermodynamic parameters. Biophys J 86:254\u2013263","journal-title":"Biophys J"}],"container-title":["EMBO Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-024-00187-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1038\/s44321-024-00187-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-024-00187-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T10:23:51Z","timestamp":1786962231000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1038\/s44321-024-00187-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,12]]}},"alternative-id":["187"],"URL":"https:\/\/doi.org\/10.1038\/s44321-024-00187-y","relation":{},"ISSN":["1757-4676","1757-4684"],"issn-type":[{"value":"1757-4676","type":"print"},{"value":"1757-4684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,9]]},"assertion":[{"value":"16 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Thomas C. Wirth, Malin Peter, Norman Woller, and Florian K\u00fchnel have filed patent applications describing the virus Ad5\/11 (WO2021239586-A1) and MATE technology (EP23162746.4).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure and competing interests statement"}}],"article-number":"5"}}